Revitalizing Dialysis Care and Research and Development in New Fields
First written in FY2016. 24 of 28 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026ReframedAnnual report
「Research and development: In addition to further developing dialysis products, we will create innovative new drugs and products that address unmet medical needs in the renal and urological fields and infertility treatment, including the focal segmental glomerulosclerosis (FSGS) treatment DMX-200 and a novel-concept embryo culture medium, thereby contributing to improved patient quality of life.」
The research and development policy has been reorganized and expanded from further developing dialysis-related products to addressing unmet medical needs in areas including DMX-200, embryo culture media, the renal and urological fields, and infertility treatment. - 2026-05-12AdvancedEarnings presentation
「A total of 333 patients, exceeding the planned 286 cases, participated in the clinical trial across 21 countries and regions, including Japan」
The company specifically disclosed the number of participating countries and regions and patients in the international joint Phase 3 trial of DMX-200. - FY2026-H1RestatedAnnual report
「There were no material changes in the status of research and development activities during the interim accounting period.」
No significant changes have been identified in research and development activities, including the revitalization of dialysis care and the development of new fields. - FY2024RestatedAnnual report
「Development of dialysis agents has been completed through the No. 5 series, which is a core source of the company’s competitive advantage. Looking ahead to developing dialysis agents with added value and expanding its range of dialysis-related products, the company is also focusing on acquiring specialized knowledge in each field. As a pioneer in this area, it is working toward developing higher-value-added products by receiving technical guidance from medical specialists.」
The company continues its R&D strategy of developing dialysis agents, expanding dialysis-related products and using technical guidance from medical specialists. - FY2024-Q3RestatedAnnual report
「There were no material changes in the status of research and development activities during the cumulative third quarter.」
The company stated that there were no material changes in the status of its research and development activities and continues its R&D strategy, including in the dialysis and new-fields areas. - FY2024-Q2RestatedAnnual report
「There were no material changes in the status of research and development activities during the cumulative second quarter.」
The company stated that there were no material changes in the status of its research and development activities and continues its R&D strategy, including in the dialysis and new-fields areas. - FY2024-Q1RestatedAnnual report
「There were no material changes in the status of research and development activities during the cumulative first quarter.」
The company stated that there were no material changes in the status of its research and development activities and continues its R&D strategy, including in the dialysis and new-fields areas. - FY2023AdvancedAnnual report
「Development of dialysis agents has been completed through the No. 5 series, which is a core source of the company’s competitive advantage. Looking ahead to developing dialysis agents with added value and expanding its range of dialysis-related products, the company is also focusing on acquiring specialized knowledge in each field. As a pioneer in this area, it is working toward developing higher-value-added products by receiving technical guidance from medical specialists.」
The company stated that development of dialysis agents had been completed through the No. 5 series and that it plans to use technical guidance from medical specialists to develop dialysis agents with added value and related products. - FY2022RestatedAnnual report
「The company is working to further revitalize dialysis care, centered on infusion products and artificial-kidney dialysis agents, while pursuing development in new fields to meet emerging medical needs.」
The company continues to pursue deepening its infusion and dialysis agent businesses and developing new fields as its R&D strategy. - FY2021RestatedAnnual report
「The company is working to further revitalize dialysis care, centered on infusion products and artificial-kidney dialysis agents, while pursuing development in new fields to meet emerging medical needs.」
The company continues to pursue deepening its infusion and dialysis agent businesses and developing new fields as its R&D strategy. - FY2021-Q3RestatedAnnual report
「There were no material changes in the status of research and development activities during the cumulative third quarter.」
The company stated that there were no material changes in the status of its research and development activities and continues its R&D strategy, including in the dialysis and biotechnology fields. - FY2021-Q2RestatedAnnual report
「There were no material changes in the status of research and development activities during the cumulative second quarter.」
The company stated that there were no material changes in the status of its research and development activities and continues its R&D strategy, including in the dialysis and biotechnology fields. - FY2021-Q1RestatedAnnual report
「There were no material changes in the status of research and development activities during the cumulative first quarter.」
The company stated that there were no material changes in the status of its research and development activities and continues its R&D strategy, including in the dialysis and biotechnology fields. - FY2020-Q3RestatedAnnual report
「For dialysis-related formulations, the company is developing new products that respond directly to the needs of medical settings, working to further revitalize the dialysis care field as it approaches maturity, and actively pursuing entry into new fields through the development of new drugs applying genetic biotechnology and other initiatives.」
The company continues to develop new dialysis-related formulations, develop new drugs applying genetic biotechnology, and enter new fields. - FY2020-Q2RestatedAnnual report
「For dialysis-related formulations, the company is developing new products that respond directly to the needs of medical settings, working to further revitalize the dialysis care field as it approaches maturity, and actively pursuing entry into new fields through the development of new drugs applying genetic biotechnology and other initiatives.」
The company continues to develop new dialysis-related formulations, develop new drugs applying genetic biotechnology, and enter new fields. - FY2020-Q1RestatedAnnual report
「For dialysis-related formulations, the company is developing new products that respond directly to the needs of medical settings, working to further revitalize the dialysis care field as it approaches maturity, and actively pursuing entry into new fields through the development of new drugs applying genetic biotechnology and other initiatives.」
The company continues to develop new dialysis-related formulations, develop new drugs applying genetic biotechnology, and enter new fields. - FY2019RestatedAnnual report
「In particular, in its medical pharmaceuticals business, which comprises its core product groups, the company is actively pursuing R&D focused on deepening its infusion and artificial-kidney dialysis agent businesses and developing new drug candidates in biotechnology-related fields.」
The company continues to deepen its infusion and dialysis agent businesses and develop new drug candidates in biotechnology-related fields. - FY2019-Q3RestatedAnnual report
「For dialysis-related formulations, the company is developing new products that respond directly to the needs of medical settings, working to further revitalize the dialysis care field as it approaches maturity, and actively pursuing entry into new fields through the development of new drugs applying genetic biotechnology and other initiatives.」
The company continues to develop new dialysis-related formulations, develop new drugs applying genetic biotechnology, and enter new fields. - FY2019-Q2RestatedAnnual report
「For dialysis-related formulations, the company is developing new products that respond directly to the needs of medical settings, working to further revitalize the dialysis care field as it approaches maturity, and actively pursuing entry into new fields through the development of new drugs applying genetic biotechnology and other initiatives.」
The company continues to develop new dialysis-related formulations, develop new drugs applying genetic biotechnology, and enter new fields. - FY2019-Q1RestatedAnnual report
「For dialysis-related formulations, the company is developing new products that respond directly to the needs of medical settings, working to further revitalize the dialysis care field as it approaches maturity, and actively pursuing entry into new fields through the development of new drugs applying genetic biotechnology and other initiatives. At the R&D Center, all employees are working to improve operational efficiency with a focus on shortening development timelines and reducing development costs, while maintaining close, continuous cooperation with the production, sales and quality assurance divisions.」
The company continues to develop new dialysis-related formulations, develop new drugs applying genetic biotechnology, enter new fields, and shorten development timelines and reduce costs. - FY2018RestatedAnnual report
「In particular, in its medical pharmaceuticals business, which comprises its core product groups, the company is actively pursuing R&D focused on deepening its infusion and artificial-kidney dialysis agent businesses and developing new drug candidates in biotechnology-related fields.」
The company continues to pursue deepening its infusion and dialysis agent businesses and developing new drug candidates in biotechnology-related fields as its R&D strategy. - FY2018-Q3RestatedAnnual report
「For dialysis-related formulations, the company is developing new products that respond directly to the needs of medical settings, working to further revitalize the dialysis care field as it approaches maturity, and actively pursuing entry into new fields through the development of new drugs applying genetic biotechnology and other initiatives. At the R&D Center, all employees are working to improve operational efficiency with a focus on shortening development timelines and reducing development costs, while maintaining close, continuous cooperation with the production, sales and quality assurance divisions.」
The company continues to develop new dialysis-related formulations, enter new fields using genetic biotechnology, and shorten development timelines and reduce costs. - FY2018-Q1RestatedAnnual report
「For dialysis-related formulations, the company is developing new products that respond directly to the needs of medical settings, working to further revitalize the dialysis care field as it approaches maturity, and actively pursuing entry into new fields through the development of new drugs applying genetic biotechnology and other initiatives. At the R&D Center, all employees are working to improve operational efficiency with a focus on shortening development timelines and reducing development costs, while maintaining close, continuous cooperation with the production, sales and quality assurance divisions.」
The company continues to develop new dialysis-related formulations, enter new fields using genetic biotechnology, and shorten development timelines and reduce costs. - FY2017RestatedAnnual report
「The company is pursuing R&D focused on deepening its infusion and artificial-kidney dialysis agent businesses and developing new drug candidates in biotechnology-related fields.」
The company continues to pursue deepening its infusion and dialysis agent businesses and developing new drug candidates in biotechnology-related fields as its R&D strategy. - FY2017-Q3RestatedAnnual report
「For dialysis-related formulations, the company is developing new products that respond directly to the needs of medical settings, working to further revitalize the dialysis care field as it approaches maturity, and actively pursuing entry into new fields through the development of new drugs applying genetic biotechnology and other initiatives. At the R&D Center, all employees are working to improve operational efficiency with a focus on shortening development timelines and reducing development costs, while maintaining close, continuous cooperation with the production, sales and quality assurance divisions.」
The company continues to develop new dialysis-related formulations, enter new fields through the application of genetic biotechnology, and shorten development timelines and reduce costs. - FY2017-Q2RestatedAnnual report
「For dialysis-related formulations, the company is developing new products that respond directly to the needs of medical settings, working to further revitalize the dialysis care field as it approaches maturity, and actively pursuing entry into new fields through the development of new drugs applying genetic biotechnology and other initiatives.」
The company continues to develop new dialysis-related formulations and enter new fields through the application of genetic biotechnology. - FY2017-Q1RestatedAnnual report
「For dialysis-related formulations, the company is developing new products that respond directly to the needs of medical settings, working to further revitalize the dialysis care field as it approaches maturity, and actively pursuing entry into new fields through the development of new drugs applying genetic biotechnology and other initiatives.」
The company continues to develop new dialysis-related formulations and enter new fields through the application of genetic biotechnology. - FY2016First statedAnnual report
「For dialysis-related formulations, the company is developing new products that respond directly to the needs of medical settings, working to further revitalize the dialysis care field as it approaches maturity, and actively pursuing entry into new fields through the development of new drugs applying genetic biotechnology and other initiatives.」
In addition to deepening its existing dialysis-related formulations business, the company’s R&D strategy includes entering new fields through the development of new drugs using genetic biotechnology.